Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Ionis Pharmaceuticals
(NQ:
IONS
)
52.78
USD
+1.51 (+2.95%)
Official Closing Price
Updated: 4:29 PM EST, Mar 5, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Ionis Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Ionis establishes new grant program to advance research and understanding of transthyretin amyloidosis
March 01, 2021
The Janice Wiesman Young Investigator Grant Program honors leading expert on neurological impact of amyloidosis
From
PR Newswire
Ionis reports fourth quarter and full year 2020 financial results and recent business achievements
February 24, 2021
Achieved 2020 financial guidance
From
PR Newswire
Ionis to present at upcoming investor conferences
February 19, 2021
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced that management will participate in a virtual fireside chat at the following investor conferences:
From
PR Newswire
Ionis to hold 2020 financial results webcast
February 11, 2021
Webcast scheduled for Wednesday, February 24 at 9:00 a.m. Eastern Time
From
PR Newswire
Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
January 08, 2021
From
GlobeNewswire News Releases
Ionis appoints Eugene Schneider, M.D., as executive vice president and chief clinical development officer
January 07, 2021
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the appointment of Eugene Schneider, M.D., as executive vice president and chief clinical development officer. In this role, Dr. Schneider...
From
PR Newswire
Ionis to present at 39th Annual J.P. Morgan Healthcare Conference
January 05, 2021
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the virtual...
From
PR Newswire
Stanley T. Crooke, Ph.D., M.D, to retire from Ionis to focus on his scientific interests and n-Lorem Foundation
December 17, 2020
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced today that its founder and executive chairman Stanley T. Crooke, M.D., Ph.D., will retire from Ionis and...
From
PR Newswire
Ionis highlights achievements, commercial strategy and technology advancements at Investor Day
December 08, 2020
- Prioritizing and preparing its growing Ionis-owned pipeline for commercialization
From
PR Newswire
Red Clover Market Size, Share, Price, Trends, Growth, Analysis, Key Players, Outlook, Report, Forecast 2020-2025 | ExpertMarketResearch.com
December 04, 2020
Tags
Research Newswire
Reportedtimes
Financial Content
From
iCrowdNewswire
Ionis to participate in virtual fireside chat at BMO 2020 Growth and ESG conference
December 02, 2020
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will participate in a virtual fireside chat at the BMO 2020 Growth and ESG Conference...
From
PR Newswire
Ionis announces initiation of the global Phase 3 BALANCE study for AKCEA-APOCIII-LRX in patients with familial chylomicronemia syndrome
December 01, 2020
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the initiation of the Phase 3 BALANCE study for AKCEA-APOCIII-LRx in adult patients with familial chylomicronemia syndrome (FCS). FCS is a...
From
PR Newswire
Ionis to hold virtual investor day event
December 01, 2020
Webcast scheduled for Monday, December 7 at 11:00 a.m. Eastern Time
From
PR Newswire
Ionis announces AstraZeneca's initiation of the Phase 2b clinical study of its antisense medicine targeting PCSK9 to lower LDL-cholesterol
November 30, 2020
Phase 1 results for ION449 (AZD8233) demonstrate best-in-class potential, showing potent, dose-dependent PCSK9 reductions of >90% with favorable safety profile
From
PR Newswire
Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development
November 23, 2020
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the biopharmaceutical company AstraZeneca has licensed ION455, an investigational antisense medicine being developed as a potential...
From
PR Newswire
Promising new data for Ionis' antisense medicine targeting PCSK9 presented at American Heart Association (AHA) Scientific Sessions 2020
November 13, 2020
- Single doses resulted in potent, dose-dependent PCSK9 reductions of up to >90%, demonstrating best-in-class potential for the treatment of patients with high cholesterol at risk of cardiovascular...
From
PR Newswire
Ionis' pioneering antisense technology to be featured in multiple presentations at American Heart Association (AHA) Scientific Sessions 2020
November 12, 2020
- Ionis' novel antisense medicine targeting PCSK9 demonstrates best-in-class potential for the treatment of patients with high cholesterol at risk for cardiovascular disease
From
PR Newswire
Ionis' antisense technology to be featured during virtual RNA at the Bench and Bedside II Conference
November 10, 2020
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that accomplished Ionis scientists will highlight the company's pioneering advancements in research and drug development in antisense...
From
PR Newswire
Ionis to present at upcoming virtual investor conferences
November 09, 2020
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following virtual investor conferences:
From
PR Newswire
Ionis reports third quarter 2020 financial results and recent business achievements
November 04, 2020
On track to achieve 2020 financial guidance
From
PR Newswire
Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx)
November 03, 2020
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary Akcea Therapeutics, Inc., today announced that Pfizer Inc. (NYSE: PFE) has initiated a Phase 2b study of vupanorsen...
From
PR Newswire
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product
October 30, 2020
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary, Akcea Therapeutics, received the Prix Galien USA Award for the Best Biotechnology Product in 2020 in recognition of TEGSEDI,...
From
PR Newswire
Ionis' third novel antisense medicine for ALS, its first designed to treat a broad ALS population, begins clinical trial
October 22, 2020
- Trial will evaluate ION541 (BIIB105) for treatment of most forms of ALS regardless of family history
From
PR Newswire
Ionis to hold third quarter 2020 financial results webcast
October 21, 2020
Webcast scheduled for Wednesday, November 4 at 11:30 a.m. Eastern Time
From
PR Newswire
Ionis antisense medicine being evaluated in an investigator-initiated clinical study of COVID-19 patients in Brazil
October 15, 2020
- Study will evaluate the effectiveness of IONIS-PKK-LRx in reducing the severity of respiratory complications in COVID-19 patients
From
PR Newswire
/C O R R E C T I O N -- Ionis Pharmaceuticals, Inc./
October 13, 2020
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that data from a clinical trial of IONIS-ENAC-2.5Rx demonstrated a significant decrease in the...
From
PR Newswire
Ionis' inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis
October 13, 2020
- Data from the first clinical study of IONIS-ENAC-2.5 Rx to be presented at North American Cystic Fibrosis Conference
From
PR Newswire
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics
October 12, 2020
Transaction creates a stronger, more efficient company
From
PR Newswire
Ionis Chief Scientific Officer Frank Bennett receives Lifetime Achievement Award from Oligonucleotide Therapeutics Society
October 01, 2020
- Ionis-authored research also recognized with Paper of the Year honor
From
PR Newswire
Ionis and Genuity Science announce agreement designed to rapidly translate genomic insights into therapeutics
October 01, 2020
Multi-year collaboration is expected to generate genetically validated targets for up to 20 diseases
From
PR Newswire
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.